Mylan and Novartis Continue to Push Back Against FDA’s Biologics Suffixes

Mylan and Novartis criticized the FDA’s use of arbitrary suffixes in a non-proprietary naming convention for biologics in comments about a Sept. 4 a public hearing aimed at promoting biosimilars and interchangeable products.
Source: Drug Industry Daily